Trademark/Service Mark Application, Principal Register
PTO- 1478
Approved for use through 02/28/2021. OMB 0651-0009
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number
Trademark/Service Mark Application, Principal Register
The mark consists of standard characters, without claim to any particular font style, size, or color.
REGISTER
Principal
APPLICANT INFORMATION
*OWNER OF MARK
Mirati Therapeutics, Inc.
INTERNAL ADDRESS
Suite 200
*MAILING ADDRESS
9393 Towne Centre Drive
*CITY
San Diego
*STATE
(Required for U.S. applicants)
California
*COUNTRY/REGION/JURISDICTION/U.S. TERRITORY
United States
*ZIP/POSTAL CODE
(Required for U.S. and certain international addresses)
92121
*EMAIL ADDRESS
XXXX
LEGAL ENTITY INFORMATION
TYPE
corporation
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY OF INCORPORATION
Delaware
GOODS AND/OR SERVICES AND BASIS INFORMATION
INTERNATIONAL CLASS
005
*IDENTIFICATION
pharmaceuticals; pharmaceutical preparations; pharmaceutical products; pharmaceutical preparations for the treatment of cancer; pharmaceutical
preparations for use in oncology; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment of lung cancer; pharmaceutical preparations for
the treatment of non-small cell lung carcinoma; pharmaceutical preparations for the treatment of colorectal carcinoma; pharmaceutical preparations for the treatment of pancreatic cancer;
pharmaceuticals comprising small molecules; pharmaceuticals comprising small molecules for the treatment of cancer; pharmaceuticals comprising small molecules for the treatment of infectious
diseases; pharmaceuticals comprising small molecules for the treatment of lung cancer; pharmaceuticals comprising small molecules for the treatment of non-small cell lung carcinoma; pharmaceuticals
comprising small molecules for the treatment of colorectal carcinoma; pharmaceuticals comprising small molecules for the treatment of pancreatic cancer; pharmaceuticals comprising compounds;
pharmaceuticals comprising compounds for the treatment of cancer; pharmaceuticals comprising inhibitors; pharmaceuticals comprising inhibitors for the treatment of cancer; pharmaceuticals for the
treatment of solid tumors; pharmaceuticals for the treatment of advanced solid tumors
FILING BASIS
SECTION 1(b)
INTERNATIONAL CLASS
042
*IDENTIFICATION
research and development of pharmaceuticals in the field of oncology; providing information in the field of scientific and medical research
related to oncology; research and development of pharmaceuticals; providing information in the field of scientific and medical research related to pharmaceuticals
FILING BASIS
SECTION 1(b)
ATTORNEY INFORMATION
NAME
Eric R. Moran
ATTORNEY DOCKET NUMBER
21-0416-US
ATTORNEY BAR MEMBERSHIP NUMBER
XXX
YEAR OF ADMISSION
XXXX
U.S. STATE/ COMMONWEALTH/ TERRITORY
XX
FIRM NAME
McDonnell Boehnen Hulbert & Berghoff LLP
INTERNAL ADDRESS
31st Floor
STREET
300 South Wacker Drive
CITY
Chicago
STATE
Illinois
COUNTRY/REGION/JURISDICTION/U.S. TERRITORY
United States
ZIP/POSTAL CODE
60606
PHONE
312-913-0001 x3302
FAX
312-913-0002
EMAIL ADDRESS
docketing@mbhb.com
OTHER APPOINTED ATTORNEY
All other attorneys at McDonnell Boehnen Hulbert & Berghoff LLP
CORRESPONDENCE INFORMATION
NAME
Eric R. Moran
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE
docketing@mbhb.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES)
moran@mbhb.com; potempam@mbhb.com
FEE INFORMATION
APPLICATION FILING OPTION
TEAS Standard
NUMBER OF CLASSES
2
APPLICATION FOR REGISTRATION PER CLASS
350
*TOTAL FEES DUE
700
*TOTAL FEES PAID
700
SIGNATURE INFORMATION
SIGNATURE
/Eric R. Moran/
SIGNATORY'S NAME
Eric R. Moran
SIGNATORY'S POSITION
Attorney of record, Illinois bar member
SIGNATORY'S PHONE NUMBER
312-913-3302
DATE SIGNED
03/25/2021
SIGNATURE METHOD
Signed directly within the form
PTO- 1478
Approved for use through 02/28/2021. OMB 0651-0009
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number
Trademark/Service Mark Application, Principal Register
Serial Number:90603915
Filing Date:03/25/2021
To the Commissioner for Trademarks:
MARK: KRAZATI (Standard Characters, see mark)
The literal element of the mark consists of KRAZATI. The mark consists of standard characters, without claim to any particular font style, size, or color.
The applicant, Mirati Therapeutics, Inc., a corporation of Delaware, having an address of
Suite 200
9393 Towne Centre Drive
San Diego, California 92121
United States
XXXX
requests registration of the trademark/service mark identified above in the United States Patent and Trademark Office on the Principal Register established by the Act of July 5, 1946 (15 U.S.C.
Section 1051 et seq.), as amended, for the following:
International Class 005: pharmaceuticals; pharmaceutical preparations; pharmaceutical products; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for use in
oncology; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment of lung cancer; pharmaceutical preparations for the treatment of
non-small cell lung carcinoma; pharmaceutical preparations for the treatment of colorectal carcinoma; pharmaceutical preparations for the treatment of pancreatic cancer; pharmaceuticals comprising
small molecules; pharmaceuticals comprising small molecules for the treatment of cancer; pharmaceuticals comprising small molecules for the treatment of infectious diseases; pharmaceuticals
comprising small molecules for the treatment of lung cancer; pharmaceuticals comprising small molecules for the treatment of non-small cell lung carcinoma; pharmaceuticals comprising small molecules
for the treatment of colorectal carcinoma; pharmaceuticals comprising small molecules for the treatment of pancreatic cancer; pharmaceuticals comprising compounds; pharmaceuticals comprising
compounds for the treatment of cancer; pharmaceuticals comprising inhibitors; pharmaceuticals comprising inhibitors for the treatment of cancer; pharmaceuticals for the treatment of solid tumors;
pharmaceuticals for the treatment of advanced solid tumors
Intent to Use: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services.
International Class 042: research and development of pharmaceuticals in the field of oncology; providing information in the field of scientific and medical research related to oncology;
research and development of pharmaceuticals; providing information in the field of scientific and medical research related to pharmaceuticals
Intent to Use: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services.
The owner's/holder's proposed attorney information: Eric R. Moran. Other appointed attorneys are All other attorneys at McDonnell Boehnen Hulbert & Berghoff LLP. Eric R. Moran of McDonnell
Boehnen Hulbert & Berghoff LLP, is a member of the XX bar, admitted to the bar in XXXX, bar membership no. XXX, and the attorney(s) is located at
31st Floor
300 South Wacker Drive
Chicago, Illinois 60606
United States
312-913-0001 x3302(phone)
312-913-0002(fax)
docketing@mbhb.com
The docket/reference number is 21-0416-US.
Eric R. Moran submitted the following statement: The attorney of record is an active member in good standing of the bar of the highest court of a U.S. state, the District of Columbia, or any U.S.
Commonwealth or territory.
The applicant's current Correspondence Information:
Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the applicant owner/holder and the applicant owner's/holder's attorney, if appointed,
and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).
A fee payment in the amount of $700 has been submitted with the application, representing payment for 2 class(es).
Declaration
Declaration Signature
Signature: /Eric R. Moran/ Date: 03/25/2021
Signatory's Name: Eric R. Moran
Signatory's Position: Attorney of record, Illinois bar member
Signatory's Phone Number: 312-913-3302
Signature method: Signed directly within the form
Payment Sale Number: 90603915
Payment Accounting Date: 03/25/2021
Serial Number: 90603915
Internet Transmission Date: Thu Mar 25 19:03:00 ET 2021
TEAS Stamp: USPTO/BAS-XX.XXX.XXX.XX-2021032519030042
2905-90603915-77065beefc1f35fd08bf42206a
55f0776ab1afd9fade682310d9488068f7de83a7
-CC-02580064-20210325184811760996